Amneal Eyes Multiple Targets As It Seeks To Maintain Momentum
Identifies A Range Of Specific Product Opportunities Amid Double-Digit Growth
Executive Summary
As Amneal reported first-quarter results, the firm’s management pointed to a number of specific product opportunities on the horizon as the company seeks to maintain growth momentum.
You may also be interested in...
Amneal Goes After ProAir, Lumigan And Diprivan With Latest Filings
With a continuing focus on complex generics, Amneal has revealed a trio of US filings targeting ProAir, Lumigan and Diprivan.
What’s Next? Five Things To Look Out For In June
Generics Bulletin previews the most notable and anticipated events for June 2023.
Amneal Continues To See Value In Complexity
With Amneal delivering what it described as a “solid” set of financials for 2022, the company has reaffirmed that it sees more value in moving increasingly into complex generics and bolstering its nascent biosimilars business.